- Home
- OZ vs ATAI Comparison
OZ vs ATAI Comparison
Compare OZ & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- ATAI
- Stock Information
- Founded
- OZ 2020
- ATAI 2018
- Country
- OZ United States
- ATAI Germany
- Employees
- OZ N/A
- ATAI N/A
- Industry
- OZ
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- OZ
- ATAI Health Care
- Exchange
- OZ Nasdaq
- ATAI Nasdaq
- Market Cap
- OZ 237.6M
- ATAI 444.7M
- IPO Year
- OZ N/A
- ATAI 2021
- Fundamental
- Price
- OZ $65.50
- ATAI $3.48
- Analyst Decision
- OZ
- ATAI Strong Buy
- Analyst Count
- OZ 0
- ATAI 3
- Target Price
- OZ N/A
- ATAI $11.67
- AVG Volume (30 Days)
- OZ 2.0K
- ATAI 8.9M
- Earning Date
- OZ 01-01-0001
- ATAI 08-12-2025
- Dividend Yield
- OZ N/A
- ATAI N/A
- EPS Growth
- OZ N/A
- ATAI N/A
- EPS
- OZ N/A
- ATAI N/A
- Revenue
- OZ $4,077,000.00
- ATAI $1,863,000.00
- Revenue This Year
- OZ N/A
- ATAI $423.05
- Revenue Next Year
- OZ N/A
- ATAI N/A
- P/E Ratio
- OZ N/A
- ATAI N/A
- Revenue Growth
- OZ 94.70
- ATAI 572.56
- 52 Week Low
- OZ $56.77
- ATAI $1.03
- 52 Week High
- OZ $82.89
- ATAI $4.00
- Technical
- Relative Strength Index (RSI)
- OZ 50.68
- ATAI 60.69
- Support Level
- OZ $65.25
- ATAI $3.06
- Resistance Level
- OZ $66.49
- ATAI $3.70
- Average True Range (ATR)
- OZ 0.33
- ATAI 0.27
- MACD
- OZ -0.02
- ATAI 0.00
- Stochastic Oscillator
- OZ 36.36
- ATAI 52.46
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.